Expression and function of the novel proto-oncogene PBF in thyroid cancer -a new target for augmenting radioiodine uptake.
Research output: Contribution to journal › Review article › peer-review
Colleges, School and Institutes
Pituitary tumor-transforming gene (PTTG)-binding factor (PBF; PTTG1IP) was initially identified though its interaction with the human securin, PTTG. Like PTTG, PBF is upregulated in multiple endocrine tumours including thyroid cancer. PBF is believed to induce the translocation of PTTG into the cell nucleus where it can drive tumourigenesis via a number of different mechanisms. However, an independent transforming ability has been demonstrated both in vitro and in vivo, suggesting PBF is itself a proto-oncogene. Studied in only a limited number of publications to date, PBF is emerging as a protein with a growing repertoire of roles. Recent data suggest that PBF possesses a complex multifunctionality in an increasing number of tumour settings. For example, PBF is upregulated by oestrogen and mediates oestrogen-stimulated cell invasion in breast cancer cells. In addition to a possible role in the induction of thyroid tumourigenesis, PBF overexpression in thyroid cancers inhibits iodide uptake. PBF has been shown to repress NIS activity by transcriptional regulation of NIS expression through the human NIS upstream enhancer (hNUE), and further inhibits iodide uptake via a post-translational mechanism of NIS governing subcellular localisation. This review discusses the current data describing PBF expression and function in the thyroid and highlights PBF as a novel target for improving radioiodine uptake and thus prognosis in thyroid cancer.
|Number of pages||7|
|Journal||Journal of Endocrinology|
|Early online date||30 Mar 2011|
|Publication status||Published - 1 Aug 2011|